Navigation Links
China Sky One Medical, Inc. Completes Acquisition of Peng Lai Jin Chuang Company
Date:9/11/2008

HARBIN, China, Sept. 11 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Amex: CSY), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that it completed the acquisition of Peng Lai Jin Chuang Company ("Jin Chuang"). The acquisition was announced on June 12, 2008 and closed on September 5, 2008.

Under the terms of the agreement, China Sky One Medical's wholly-owned subsidiary, Harbin Tian Di Ren Medical Science and Technology Company, acquired 100% of Jin Chuang's assets for a cash payment of approximately $7.1 million, consisting of $2.5 million in cash and $4.6 million of China Sky One Medical's common shares. Jin Chuang is a newly established pharmaceutical company that has obtained Good Manufacturing Practice Certification (GMP) approval issued by the country's State Food and Drug Administration (SFDA). Its assets include franchise, production and operating rights to a portfolio of twenty (20) medicines approved by the SFDA for the treatment of colds cardiovascular disease, and depression.

"This acquisition complements our business, and we expect to realize greater synergies as we incorporate Jin Chuang's assets and broaden our manufacturing capabilities and product line even further," said Mr. Yan-qing Liu, Chairman, CEO and President of China Sky One Medical. "Even though Jin Chuang is a newly established company not begun to manufacture, we expect it will begin to contribute to our profitability at the end of 2008."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company, Harbin First Bio- Engineering Company Limited, and Heilongjiang Tianlong Pharmaceutical, Inc., the Company manufactures and distributes over-the- counter pharmaceutical products, which make up its major revenue source. For more information, visit http://skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

For more information, please contact:

Company Contact:

China Sky One Medical, Inc.

Mr. Yu-bo Hao, Board Secretary

Tel: +86-0451-53994069

Email: china_sky_one@yahoo.cn

Investor Relations Contact:

CCG Investor Relations

Mr. Crocker Coulson, President

Tel: +1-646-213-1915

Email: crocker.coulson@ccgir.com

Mr. Richard Micchelli, Financial Writer

Tel: +1-646-454-4516

Email: richard.micchelli@ccgir.com

Web site: http://www.ccgir.com


'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Yingxia International, Inc. Appoints New Vice President of Finance
2. China-Biotics, Inc. Provides Update on Construction of New Manufacturing Facility
3. China Biologic Products to Present at the SIG Beijing Management Summit
4. China Biologics Production Facility Renews GMP Certification
5. China Bio Energy Holdings Group Announces Participation in the Susquehanna Second Annual Beijing Management Summit
6. Plexus Announces Expansion in Hangzhou, China
7. China Sky One Medical, Inc. Approved to List on the NASDAQ Global Market
8. China Pharma Holdings, Inc. Will Attend the Susquehanna Financial Group, LLP (SIG) Beijing Management Summit
9. ORBIS and Alcon Train Chinas Next Generation of Sight-Savers
10. China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base
11. MicuRx Pharmaceuticals Selects Next-Generation Antibiotic Candidate Targeting MRSA and Expands Operation in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2017)... Linda, Ca (PRWEB) , ... August 14, 2017 ... ... for poorly characterized and performing antibodies. Key researchers in the antibody community have ... proper characterization and consistency for antibodies in the laboratory. , The ...
(Date:8/14/2017)... NY (PRWEB) , ... August 14, 2017 , ... ... Clinical Trials event, which will take place on September 6, 2017 at the ... Karlin, MD , Head of Experimental Medicine, Informatics, and Regulatory Strategy, Pfizer Innovative Research ...
(Date:8/11/2017)... ... ... A staple in the community for more than 60 years, Bill Miller ... a new digital marketing strategy and updated logo. , As part of the initiative ... the South Texas Blood & Tissue Center for the month of August. , ...
(Date:8/11/2017)... WI (PRWEB) , ... August 11, 2017 , ... ... in food production, and, in particular, more natural alternatives to synthetic ingredients,” said ... innovation of Third Wave, with the established manufacturing presence and know-how of Biorigin ...
Breaking Biology Technology:
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
(Date:3/22/2017)... 21, 2017 Optimove , provider ... retailers such as 1-800-Flowers and AdoreMe, today announced ... and Replenishment. Using Optimove,s machine learning algorithms, these ... and replenishment recommendations to their customers based not ... of customer intent drawn from a complex web ...
Breaking Biology News(10 mins):